← Russell 3000 cross-section

DNA Ginkgo Bioworks Holdings, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$508m
Revenue TTM
$112m
Net income TTM
$-291m
Free cash flow
$-175m
Composite score
25.2
Sector rank
#2391

Valuation

P / E
EV / EBITDA
EV / sales
3.8
FCF yield
-34.43%
Earnings yield vs 10-yr
-62.00pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-260.0%
EBITDA margin
ROE
-69.2%
ROIC
-86.6%
Revenue growth
-51.5%

Insider activity, last 90 days

Net open-market
$-0.01m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Components of Results of Operations Revenue We generate revenue primarily through service and license agreements for our tools and solutions offerings. Our R&D expenses were lower in the first half of 2026 compared to the first half of 2025, primarily due to our restructuring plan announced and commenced in the second quarter of 2024 as we rationalized our current development programs and prioritize our investments in our tools offerings. We expect that our R&D expenses will either remain consistent or decline in 2026 as compared to 2025, reflecting the stabilization of our operational overhead and the impact of our restructuring actions. …Ginkgo Bioworks Holdings, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →